Peptron's animal half-life lead: competitors' is longer, and evidence for once-monthly human weight loss remains unclear
Predicted impact: Medium
Report questions drug half-life edge and monthly dosing evidence; follows earlier critical reports.
Peptron펩트론
087010 · KOSDAQ · ₩087010 · 펩트론
₩95,600▼ ₩2,700 (2.75%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −64.98%
- Market cap
- ₩2.2T
- Enterprise value
- ₩2.2T
- P/E
- —
- P/B
- 17.2×
- Dividend yield
- 0.0%
- ROE
- −15.9%
- Net margin
- −342.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−75.6% from the high
₩79,200Today: ₩94,300 – ₩102,300₩392,500
Returns
- 1W−5.5%
- 1M−34.3%
- 3M−33.1%
- 6M−64.7%
- YTD−62.4%
- 1Y−65.0%
- Volume today
- 160,451
- 0.5× the 20-day average
- Traded today
- ₩16B
- Listed shares
- 23,317,350
- EPS (12 months)
- −₩881
- Earnings yield −0.9%
AI research · InitiationPeptron: Loss-making KOSDAQ biotech sees share price fall 69.6% in a year while revenue stays smallThe filed numbers show a small, loss-making company with low leverage but heavy cash use, valued at about ₩2.1T.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 41: paper buys.
- SentimentNegativeNews: Article raises doubts about the company's drug lead versus rivals. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-32.7% over the last month; the price is below its 20-day average.
- News impactSome4 news items and filings in two weeks; 0 rated high impact, 3 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 26: sell ₩1.5B at the close (4.7% of 20-day average trading value)
On its 34 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 9.5% of trading value and pointed the same way 29 of 34 times.
- 2× KODEX KOSDAQ150 Leverage −₩1.3B
- -1× KODEX KOSDAQ150 Futures Inverse −₩106M
- 2× TIGER KOSDAQ150 Leverage −₩94M
- 2× RISE KOSDAQ150 Futures Leverage −₩27M
- -1× TIGER KOSDAQ150 Futures Inverse −₩2.9M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.9%
- KODEX KOSDAQ150 Leverage2×0.9%
- TIGER KOSDAQ1500.9%
- RISE KOSDAQ1500.9%
- TIGER KOSDAQ150 Leverage2×0.9%
- ACE KOSDAQ 1500.9%
- KIWOOM KOSDAQ1500.9%
- SOL KOSDAQ1500.9%
Estimated from the funds' index or underlying stock.
Peptron stock overview
Peptron (펩트론, KRX: 087010) is listed on KOSDAQ, in the Biotech & Pharma sector. The company designs and manufactures sustained-release smart drugs based on its peptide engineering and drug-release-extension technologies, and develops peptide-based new drugs. Its shares closed at ₩95,600 on Oct 27, 2026, down 2.75% on the day, giving it a market value of ₩2.2T.
Key facts
- Market cap
- ₩2.2T
- Sector
- Biotech & Pharma
- Latest price change
- −2.75%
- As of
- Oct 27, 2026
- Main business
- The company designs and manufactures sustained-release smart drugs based on its peptide engineering and drug-release-extension technologies, and develops peptide-based new drugs.
Quick answers about Peptron
- What does Peptron do?
- The company designs and manufactures sustained-release smart drugs based on its peptide engineering and drug-release-extension technologies, and develops peptide-based new drugs. It has built a GMP-grade large-scale manufacturing facility that supports clinical trials and commercial production. Its revenue comes from research peptide materials, sustained-release drug products, contract development and manufacturing, R&D services, and drug wholesale, with operations in Korea and export sales abroad.
- What is the market cap of Peptron?
- The market capitalisation of Peptron was ₩2.2T at the close on Oct 27, 2026.
- Who are the largest shareholders of Peptron?
- According to the latest official filings, the largest reported holders are Choi Ho-il (8.28%, as of Jul 14, 2026); Samsung Asset Management (4.08%, as of May 29, 2026); National Pension Service (1.63%, as of Dec 31, 2025).
- When is the next earnings report from Peptron?
- Korean companies rarely announce results dates in advance. Based on when Peptron filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Peptron?
- Yes. The National Pension Service held 1.63% of Peptron shares as of Dec 31, 2025.
Company profile
The company designs and manufactures sustained-release smart drugs based on its peptide engineering and drug-release-extension technologies, and develops peptide-based new drugs. It has built a GMP-grade large-scale manufacturing facility that supports clinical trials and commercial production. Its revenue comes from research peptide materials, sustained-release drug products, contract development and manufacturing, R&D services, and drug wholesale, with operations in Korea and export sales abroad.
Written by AI from the company's latest annual report.
- Korean name
- 펩트론
- Sector
- Biotech & Pharma
- CEO
- 최호일
- Founded
- Nov 1997
- Listed
- Jul 2015
- Listed shares
- 23,317,350
- Fiscal year ends
- Month 12
- Website
- www.peptron.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
[MK Signal] Peptron Rises on Global Expectations for SmartDepot Technology; 11.26% Gain Since MK Signal Recommendation
Predicted impact: Low
Media stock-pick recommendation performance; no company-specific new fact.
Peptron receives ₩1B instead of ₩4B after Yuhan terminates ₩4B technology transfer contract
Predicted impact: Medium
Yuhan terminates ₩4B tech transfer contract; Peptron receives ₩1B, about 0.04% of market value.
Recent filings
See all- [Corrected] New Facility Investment, etc.Sep 3, 2026
- Major management matter relevant to investorsAug 25, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportJul 14, 2026
- Insider shareholding reportJul 14, 2026
Titles in Korean until English translations are added.
Also known as: Peptron / 펩트론 / 087010 / KRX:087010
Source: KRX statistical information